PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Methylphenidate

Drugs in development · updated 30 October 2026

Methylphenidate: clinical trials and development status

Other names and codes: Concerta, Relexxii, Adhansia Xr, Jornay Pm, Quillichew Er

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 28 February 2025

As of 30 October 2026 Methylphenidate is in 26 active clinical trials (recruiting or ongoing, phases I–III) for 32 diseases. The most advanced phase is III.

26Active trials
IIIMost advanced phase
32Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Methylphenidate and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 32 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Attention deficit hyperactivity disorderIII6NCT05842330
FatigueIII3NCT05880342
DepressionII–III2NCT05474846
NeoplasmIII2NCT06905587
Prostatic NeoplasmsII–III2NCT03772834
Anxiety disorderII–III1NCT05474846
Brain NeoplasmsIII1NCT06905587
MetastasisIII1NCT03525873
RecidivismIII1NCT05842330
Treatment Adherence and ComplianceIII1NCT05842330
Post-traumatic stress disorderII3NCT07904000
AlcoholismII1NCT07306078
Alzheimer's diseaseII1NCT07279740
Chronic painII1NCT05285683
DementiaII1NCT07279740
Emotional self-regulationII1NCT05133804
Hematologic neoplasmII1NCT01628029
Parkinson's diseaseII1NCT05669170
Sleep-wake disorderII1NCT01628029
Type-1 diabetesII1NCT05957055
Cognitive dysfunctionI1NCT07226219
ComaI1NCT03814356
Disorder of consciousnessI1NCT03814356
Down syndromeI1NCT05301361
Fragile X syndromeI1NCT05301361
Intellectual disabilityI1NCT05301361
Sickle-cell diseaseI1NCT07226219
Borderline personality disorderEarly I1NCT06759298
Cerebral palsyEarly I1NCT05675098
Neurodevelopmental disorderEarly I1NCT05675098

Everything on Methylphenidate

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch